IMPORTANCE Evidence for application of stereotactic and other conformal radiotherapy techniques in treating brain tumors is largely based on data derived from dosimetric, retrospective, or small prospective studies. Therefore, we conducted a randomized clinical trial of stereotactic conformal radiotherapy (SCRT) compared with conventional radiotherapy (ConvRT) evaluating clinically meaningful end points.
R adiotherapy, when indicated in benign brain tumors and residual and/or progressive low-grade gliomas, achieves excellent long-term local control but is tempered with the risk of developing long-term sequelae and impact on their quality of life. Radiotherapy continues to evolve based on technological advances in techniques and precision of delivery. Evidence for adopting these techniques in brain tumors is largely based on demonstrating dosimetric superiority of modern radiation delivery, and retrospective and relatively small prospective clinical studies with short follow-up. [1] [2] [3] [4] [5] We therefore conducted a prospective, randomized, clinical trial of stereotactic conformal radiotherapy (SCRT) compared with conventional radiotherapy (ConvRT). The study was designed to address the most clinically relevant long-term end points in brain tumor survivors in the era of contemporary practice.
Methods

Study Population
Between April 2001 and March 2012, 200 children and young adults with low-grade and benign residual and/or progressive brain tumors were invited to participate in the study. Eligible patients were between ages 3 and 25 years with tumors measuring up to 7 cm maximum dimension on imaging and required radiotherapy in view of residual or progressive disease to achieve effective and durable long-term tumor control.
Study Design and Treatment
The present trial is a single-center phase 3 randomized study comparing efficacy of SCRT with ConvRT. Patients were randomized to SCRT or ConvRT ( Figure 1 ) based on a computergenerated stratified block randomization method with stratification parameters of tumors within or more than 2 cm of the hypothalamic-pituitary-adrenal axis (HPA), as well as patient prepubertal vs postpubertal status, neurological performance scale score (0-1 vs 2-3), and whether patients had no or minimal vs moderate or severe hydrocephalus. The study was approved by the institutional ethics committee of the Tata Memorial Centre and conducted in adherence to principles of good clinical practice, and patients provided informed consent. The allocation sequence, enrollment, and assignment of participants to interventions, and data storage and analysis were done by a clinical research secretariat at Tata Memorial Centre. Outcome measure assessors (neuropsychologists and endocrinologists) did not have access to information regarding the allocated arm. The trial protocol is available online (Supplement 1). Details of radiotherapy planning have been described previously. 6 Briefly, patients in SCRT and ConvRT arms were immobilized using relocatable stereotactic frame 7 (Brain-LAB) and a customized thermoplastic mold. Patients underwent contrast-enhanced planning computerized tomography (CT) scans with 2 to 5 mm slice thickness. In the SCRT arm, additional magnetic resonance imaging (MRI) scans were fused with planning CT scans. In the SCRT arm, gross tumor volume (GTV) was contoured on planning CT-MRI fused images, and GTV was contoured on planning CT slices in the ConvRT arm. The GTV was expanded by 5 mm in 3 dimensions to generate clinical target volume for possible microscopic disease extension. For SCRT, a margin of 2 to 3 mm was added around clinical target volume to generate planning target volume, and plans typically involved 6 to 9 noncoplanar conformal fields using 6 megavoltage photons shaped by micro-multileaf collimators (eFigure 1A and B in Supplement 2). In ConvRT, margins ranged from 1 to 2 cm to achieve appropriate planning target volume coverage, and treatment was typically delivered with 2 to 4 open fields using 6 megavoltage photons and optimized with beam modifiers. Radiotherapy dose prescription in both arms was identical (54 Gy in 30 fractions over 6 weeks [to convert Gy to rad, multiply by 100]) prescribed at isocenter to achieve homogenous dose distribution 8 (eFigure 2inSupplement 2). A posttreatment MRI was performed 6 to 12 weeks after completing radiotherapy, acting as a suitable baseline for future reference, and neuropsychological and neuroendocrine evaluations were done at regular intervals per protocol.
Statistical Considerations
The primary end points of the study were incidence and magnitude of neurocognitive and neuroendocrine dysfunctions in 2 arms. Neuropsychological assessments and neuroendocrine hormone evaluations are listed in eTables 1 and 2 in Supplement 2. A planned sample size of 200 patients was estimated to detect a reduction in intelligence quotient (IQ) from 25% to 10% and a reduction in neuroendocrine dysfunction from 70% to 50% at an α level of .05 and statistical power of 80% assuming 10% attrition rate. Results were analyzed on an intention-to-treat approach. All continuous and categorical data were compared using t tests and χ 2 tests.
Linear mixed-effect regression models with random intercepts specified for patients and slopes were modeled as fixed effects to test the primary hypothesis of a difference in rate of change in IQ scores between 2 arms overall and in stratified subgroups. For anxiety and depression, only 2 time points (baseline and 5 years) were considered for analysis using repeated-measures analysis of covariance (ANCOVA).
Overall survival and tumor control were defined as time from randomization until death or last follow-up and local failure, respectively. Survival probabilities were plotted using the Kaplan-Meier method, and respective comparisons between the 2 arms were carried out using log-rank tests. Trend in incidence of new neuroendocrine dysfunctions in both arms were obtained using a χ 2 test for trends in proportion, and slopes obtained were compared between 2 arms using t tests. All P values were based on 2-sided hypothesis tests and were not adjusted for multiple testing. The relative decline in IQ scores from baseline to 5 years was analyzed using the following formula: relative change expressed in percentage = (IQ baseline− IQ 5-year )/IQ baseline × 100. Five point (3%) and 10 point (5%) declines in full-scale IQ (FSIQ) function were considered clinically significant and considered as cut-off values. Analysis was performed with 2 categorical age ranges (≤16 and >16 years) corresponding to transition of cognitive measures scales from Wechsler Intelligence Score Chart to Wechsler Memory Scale. Statistical analysis was performed using SPSS version 21 (IBM) and Stata version 12.0 (StataCorp LLC).
Results
Both SCRT and ConvRT arms were well matched with respect to demographic variables, tumor factors, and clinical characteristics at baseline ( Table 1) . Median (interquartile range) follow-up for the entire cohort was 61 (31-86) months. Mean scores of all neurocognitive subdomains assessed over a period of 5 years between SCRT and Conv RT arms are reported in Table 2 . At baseline preradiotherapy evaluation, mean scores across most of the neurocognitive subdomains in both arms were similar ( Figure 2A and B). Mean FSIQ scores of patients in the SCRT arm were either stable or showed an improvement over 5 years compared with patients in the ConvRT arm (difference in slope = 1.48; P = .04). In contrast, mean FSIQ scores in the ConvRT arm initially improved in the first 6 months and then gradually declined, reaching preradiotherapy baseline scores by the second year and remaining stable thereafter. Neurocognitive improvement was more pronounced in subdomains of the performance quotient and memory quotient in the SCRT arm (difference in slope = 1.64; P = .04) than ConvRT arm (difference in slope = 0.76; P = .45). However, in the verbal quotient (VQ) subdomain, mean scores showed a progressive decline in both arms over 5 years (difference in slope = 0.976; P = .24), although this rate of decline was slower in the SCRT arm than in the ConvRT arm. From the fourth year onward, mean VQ scores had started to stabilize or improve in SCRT arm than ConvRT arm. A subgroup analysis showed that patients with neurological performance scale scores of 2 to 3 seemed to derive more benefit when treated with SCRT compared with ConvRT (difference in slope = 3.35; P = .05) (eFigure 3A-D in Supplement 2). Patients with moderate-to-severe hydrocephalus had better but insignificant long-term mean FSIQ scores in the SCRT arm compared with the ConvRT arm (difference in slope = 2.19; P = .09). Stereotactic conformal radiotherapy seemed to preserve long-term mean FSIQ in patients with supratentorial tumors better compared with infratentorial tumors, and SCRT was significantly beneficial in patients 16 years or younger (SCRT, 67% vs ConvRT, 37%; P = .05; eFigure 3D in Supplement 2) compared with patients older than 16 years (SCRT, 100% vs ConvRT, 83%; P = .47; eFigure 3D in Supplement 2) in mean FSIQ scores compared with patients in the ConvRT arm. When compared with baseline, at 5 years, there was reduction in anxiety and depression scores in both SCRT and ConvRT arms, but these reductions were not statistically significant (eTable 3 in Supplement 2).
Nearly two-thirds of the 200 patients included in this study had a deficit in at least 1 hormone axis at the preradiotherapy baseline level, with growth hormones being the most common deficit overall (n = 69 [38%]). The cumulative percentage incidence of neuroendocrine dysfunction over 5 years was significantly lower in the SCRT arm than in the ConvRT arm (difference in slope = .04; P = .01) with an absolute difference of 21 percentage points at 5 years ( Figure 2C ). The cumulative incidence of developing a new neuroendocrine axis dysfunction in patients with existing dysfunctions at baseline was also significantly lower in the SCRT arm (difference in slope = .04; P = .02) ( Figure 2D ). Stereotactic conformal radiotherapy minimized the incidence of new hormonal dysfunction in patients having normal preradiotherapy neuroendocrine functions compared with ConvRT. Twenty-five patients (26%) treated with SCRT maintained normal hormonal functions in all axes compared with only 13 (15%) patients treated with ConvRT (P = .05). On a subgroup analysis, tumors close (< 2 cm) to the hypothalamic-pituitary-adrenal axis (HPA) seemed to have the maximal beneficial effect with SCRT in terms of preservation of neuroendocrine dysfunction (difference in slopes = 0.048; P = .04; eFigure 4 in Supplement 2).
The 5-year tumor control rate for the SCRT arm was 93% (95% CI, 84%-98%) and 92% (95% CI, 83%-96%) for the ConvRT arm (P =.4 9)( Figure 3A) . Tumor progression was observed in 7 patients each in the SCRT arm and ConvRT arm. At the time of progression, patients were managed with a range of attempted salvage therapies including reexcision, chemotherapy, and supportive care only; 6 of these patients in the SCRT arm and 5 in the ConvRT arm experienced disease progression. Additionally, 3 patients in the SCRT arm and 2 patients in the ConvRT arm died due to postoperative complications before starting radiotherapy or at time of salvage interventions. There were also 5 non-disease-related deaths in the SCRT arm and 4 in the ConvRT arm There were 14 and 11 deaths in the SCRT and ConvRT arms, respectively. For the entire cohort of 200 patients, as per intent-to-treat analysis, 5-year rate of overall survival in the SCRT arm was 86% (95% CI, 76%-92%) and 91% (95% CI, 83%-95%) for the ConvRT arm (P = .54) ( Figure 3B ).
Discussion
Randomized clinical trials to test the efficacy of radiotherapy techniques are challenging to perform. High-precision conformal techniques such as stereotactic radiosurgery and/or a Others include ganglioglioma (n = 4), oligodendrogliomas (n = 2), pineocytoma (n = 1), schwannoma (n = 1), hemangiopericytoma (n = 1). While the present study has tested SCRT, the results of the study in principle should apply for other available conformal techniques using conventional fractionation. Stereotactic techniques of single or hypofractionation however use higher doses per fraction, and data from the present trial may not be directly applicable to them. The present study shows superiority of the forward planning-based SCRT technique that was considered to be optimal at the time of initiation of the trial over conventional open-field radiotherapy involving relatively simple planning. Over a period of time, several advances have refined various steps of radiotherapy planning processes, including accurate techniques of target volume delineation (thin-slice planning CT, MRI, automatic MRI fusion algorithms, autosegmentation, etc). Incorporation of inverse planning algorithms used in intensity-modulated radiotherapy, including recent introduction of volumetric modulated arc therapy and helical tomotherapy along with image guidance, have further improved the conformality of radiotherapy plans and precision in treatment delivery. Particle beam therapy such as protons and heavy ions are being increasingly used in clinical practice and offer unique physical and biological advantages over conventional photons. All these recent advances are likely to further minimize some of the late sequelae, thereby improving the therapeutic ratio, a proof of concept validated by the present randomized study.
Long-term cognitive function in brain tumor survivors is a major issue in clinical practice. These dysfunctions could be associated with numerous patient-related, disease-related, and treatment-related parameters. It is difficult to ascertain the exact contribution of each of these factors, although radio- Shown are the trends and the difference in slopes of the various neurocognitive subdomains in patients longitudinally followed up for 5 years; the difference in slopes between the stereotactic conformal radiotherapy (SCRT) and conventional radiotherapy (ConvRT) arms were compared by linear mixed model. Also shown are the cumulative percentage differences in endocrine dysfunction between SCRT and ConvRT arms. Slope estimates of the 2 groups were compared using t tests. RT indicates radiotherapy.
SCRT vs ConvRT for Treatment of Benign and Low-Grade Brain Tumors
Original Investigation Research jamaoncology.com (Reprinted) JAMA Oncology October 2017 Volume 3, Number 10 1373 therapy remains one of the important factors. Our study has demonstrated a favorable outcome in terms of stabilization and improvement in several neurocognitive domains evaluated longitudinally over 5 years in patients treated in the SCRT arm. This is an important finding that should help clinicians judiciously use high-precision radiotherapy when indicated. Our data showed a progressive reduction in the VQ scores over the entire follow-up period in both arms, which was gradual and stabilized over a period of time in the SCRT arm. However VQ in ConvRT arm-treated patients continued to showed a progressive decline on follow-up. Verbal quotient decline in both arms could be because majority of the patients had tumors in sellar and/or suprasellar and parasellar locations resulting in relatively high dose spillage to adjoining temporal lobes and hippocampi, both being increasingly shown to be critical in cognitive function preservation. Higher doses to the left temporal lobe and, more precisely, the limbic structures (hippocampus and the parahippocampal gyrus) have shown statistically significant positive correlation with decline in cognitive function, especially in verbal learning and auditory learning domains 15-17 that could have influenced the decline in VQ scores in our patients, irrespective of the radiotherapy technique used. Possible confounding factors-including hydrocephalus, tumor location, and performances status-did not influence the outcomes between the 2 arms significantly. Neuroendocrine dysfunction in patients with brain tumors occurs due to direct involvement of the HPA by the tumor or due to surgery and/or radiation injury, especially for tumors close to the HPA. 18 The frequency and severity of neuroendocrine dysfunction has been shown to be significantly higher in sellar and parasellar tumors in view of their proximity to the HPA, as well as owing to the use of radiotherapy, higher radiation dose, higher dose per fraction, and younger age at radiation. 19 Dosimetric studies have previously shown that SCRT techniques have a potential to deliver lesser doses to the HPA and preserve neuroendocrine function. 20 Our study has proven conclusively that patients treated with SCRT had significantly less incidence of new axes impairment compared with patients treated with conventional radiotherapy. Moreover, patients with a tumor located close to the HPA treated with SCRT had less risk of developing new neuroendocrine dysfunction compared with ConvRT, but the beneficial effect of SCRT was less apparent in tumors located further from the HPA. One of the primary aims of any therapeutic radiation is to achieve durable long-term tumor control. The concerns with introduction of high-precision radiotherapy techniques using tight margins and rapid dose fall-off was to evaluate the incidence of any marginal local failures both in the short-term and long-term. This end point was therefore incorporated while designing the present trial. Our study, demonstrating excellent long-term tumor control rates in residual and/or progressive benign and low-grade brain tumors, addresses this issue quite adequately. Craniopharyngioma was the most common tumor treated in our study (82 patients). There is growing evidence of adopting conservative surgery followed by conformal radiotherapy protocols in patients with incompletely resected and/or recurrent craniopharyngiomas for achieving maximal local control and avoiding complications of radical surgery. 21 In the present study, the long-term local control rates for the cohort of craniopharyngiomas in the SCRT arm was 97%, and 96% at 5 years in the SCRT and ConvRT arms combined, consistent with other published experiences. 21, 22 A phase 2 study of conformal radiotherapy in midline craniopharyngiomas and low-grade gliomas demonstrated the advantage of using high-precision conformal radiotherapy in stabilizing verbal learning and visual auditory learning domains. 23 In the present study, children diagnosed with craniopharyngiomas SCRT ConvRT A, The local control rate was 95% (95% CI, 88%-98%) for stereotactic conformal radiotherapy (SCRT) and 93% (95% CI, 85%-97%) for conventional radiotherapy (ConvRT) (P = .49). B, The overall survival rate was 86% (95% CI, 76%-92%) for SCRT and 91% (95% CI, 83%-95%) for ConvRT (P = .54).
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showed improvement in long-term mean FSIQ sores in the SCRT arm compared with the ConvRT arm, reiterating the importance of reducing the radiation exposure of healthy normal brain tissue without altering the treatment efficacy, thereby minimizing the risk of adverse effects. Large cooperative group studies 24,25 have shown pediatric low-grade gliomas to have a 5-year progression free survival in the range of 30% to 40%. Indeed, many of these children experience multiple tumor progressions. Despite this, a large proportion of these patients will experience long-term survival with a prolonged course that extends into adulthood. Radiotherapy has been traditionally used in these tumors, showing somewhat superior progression-free survival compared with historical studies using chemotherapy alone. 14,26 A recent study from Johns Hopkins 27 of 34 pediatric low-grade gliomas treated with conformal radiotherapy demonstrated a 10-year overall survival rate of 92% and progression-free survival rate of 72% at a median follow-up of 9.8 years. 27 Due to the concerns regarding the long-term adverse effects of RT in these patients, however, 28 other optionsincluding observation, systemic chemotherapy 29 and, more recently, targeted therapy-are being increasingly used. 30 However, both these approaches have their own limitations. Chemotherapy needs to be given for a long time, sometimes for years. In addition, resistance to treatment is a common phenomenon among patients using contemporary drugs. These factors can lead to the use of multiple lines of salvage chemotherapy, with their associated adverse effects. In the initial phase of our study, we accrued patients with both hemispheric and optic pathway gliomas per discussion of each case in the institutional joint disciplinary board policy, but with later studies demonstrating long-term adverse effects in the form of vascular events and secondary radiation induced malignancies, 28, 31 we limited the accrual of these tumors in the later part of the study.
Limitations
Limitations of the study include a relatively long time to accrue patients included in our cohort. One might argue that the conventional radiotherapy technique used in this study is rarely used in the contemporary practice, despite being time tested over decades of clinical practice, although it is still used in parts of the world, especially parts with resource constraints. Another possible limitation could be the inclusion of several tumor types, which, along with other factors such as tumor location and patient age, could possibly influence cognitive function in varying domains. Although we are cognizant that our patient population included various histologies of benign or low-grade brain tumors, we have chosen simple cognitive end points of IQ, which are universally accepted and relatively easy to evaluate in clinical practice. The subgroup analysis performed in our study had a small number of patients and results therefore need cautious interpretation.
Conclusions
The present prospective randomized, clinical trial with longterm follow-up provides a high level of evidence in favor of SCRT over ConvRT in young patients with brain tumors, improving their functional outcomes with maintenance of excellent long-term tumor control, and could provide an appropriate template for studying other newer high-precision radiotherapy techniques in the future. Author Contributions: Dr Jalali had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Jalali, Goswami, Shah, Menon, Sarin. Acquisition, analysis, or interpretation of data: Jalali, Gupta, Goda, Goswami, Dutta, Krishna, Deodhar, Kannan, Sarin. Drafting of the manuscript: Jalali, Goda, Dutta, Krishna, Menon, Kannan. Critical revision of the manuscript for important intellectual content: Jalali, Gupta, Goswami, Shah, Deodhar, Sarin. Statistical analysis: Jalali, Gupta, Goda, Goswami, Dutta, Kannan. Jalali and colleagues and the patients who participated in this trial 1 are to be commended for making an invaluable contribution to the literature concerning the understanding of radiation effects. In their prospective randomized clinical trial, Jalali and colleagues describe randomized pediatric and young adult patients with a rare group of low-grade and benign brain tumors to treatment with 1 of 2 radiation therapy techniques. The randomization was stratified for known prognostic factors, including tumor distance to the hypothalamicpituitary-adrenal axis, pubertal status, baseline neurologic performance, and baseline hydrocephalus. Patients in one arm received standard-of-care conventional radiation therapy (ConvRT), and those in the other received stereotactic conformal therapy (SCRT). Patients in both arms received a radiation dose of 54 Gy (to convert to rad, multiply by 100) delivered in 30 fractions to the tumor target volume. With ConvRT, the target volume was defined on computed tomography (CT) images and patients were immobilized with a face mask; the target dose was delivered through 4 fields to the CT-defined target volume plus a 1-to 2-cm target volume expansion to account for uncertainties in imaging accuracy and possible variations in daily treatment setup. With the SCRT technique, the target was defined on fused CT and magnetic resonance (MR) images, the patient was immobilized with a stereotactic head frame, and the dose was delivered through 6 to 9 noncoplanar fields to the target volume plus a 2-to 3-mm expansion. The use of additional fields with a smaller target volume expansion in the SCRT technique resulted in a moderate-tohigh dose volume that was much smaller than the moderateto-high dose volumes on the ConvRT arm and conformed more
Related article page 1368
Research Brain tumours are the commonest solid tumours in children and with appropriate treatment, nearly half of them achieve long 79 term cure (1,2,3). Radiotherapy is essential in the management of a majority of these tumours. Conventional radiotherapy 80 Patient Initial SCRT NO. alone or in combination with surgery and/or chemotherapy in tumours such as optic gliomas, hypothalamic gliomas, 81 craniopharyngiomas, germ cell tumours, and other low grade tumours achieves excellent long term control rates ranging from 82 70 to 95% (1,3,4,5). However, while the tumour control has been effective, there have been concerns about treatment related 83 morbidity. 84
EFFICACY OF STEREOTACTIC CONFORMAL RADIOTHERAPY (SCRT) COMPARED TO CONVENTIONAL
Long term sequelae in paediatric brain tumour survivors 85
In the only population based study done so far from Western Sweden, it was found that approximately one half of the children 86 with any type of brain tumour become long term survivors (2). A wide range of sequelae were however seen, which included 87 cognitive dysfunction in 38%, motor deficit in 25%, visual impairment in 20%, hormonal dysfunction in 20% and 88
psychological-emotional problems in 14% of the survivors. In another study, 342 adults who had brain tumours before the age 89 of 20 years, survived at least 5 years, and reached 21 years of age were compared to 479 matched siblings as controls (6). 90
Survivors of brain tumours reported a significantly higher risk for adverse outcomes such as unemployment, health conditions 91 that affected their ability to work, inability to drive or some described their current health as poor. 92
Neuropsychological and cognitive dysfunction: 93
Unfavourable neuropsychological, cognitive and functional status has been reported in 20% to 60% of the long-term survivors. 94
It has been shown to be associated with various patient, disease and treatment related parameters such as tumour in the 95 supratentorial region (2,6,7,8), tumour involving hypothalamus (7,9) or brain stem (10,11), hydrocephalus (7), absence of 96 shunt (12), uncorrected hormone deficiency (9), epilepsy (8), use of chemotherapy (11) or radiotherapy (2, 3, 6, 13, 14) . Within 97 the irradiated group, young age at radiotherapy (7,9,11,12), large volume of brain irradiated (7) and a higher radiation dose 98 (15) have been associated with a greater neuropsychological and cognitive dysfunction. 99
It is difficult to ascertain from these reports the exact contribution of each of these factors and how they interact with each 100 other. Radiotherapy is believed to be at least partly responsible although its exact role is yet to be quantified. In the only study 101 done studying various factors on a multivariate analysis, it was found that as high as one third of the 57 survivors treated with 102 radiotherapy at < 3 years of age were mentally retarded and epilepsy was the only significant variable independently 103 associated with poor cognitive dysfunction (8). Most of the evidence regarding post-radiotherapy neuropsychological and 104 cognitive dysfunction is from retrospective studies involving whole brain radiotherapy. In a few studies where the effects have 105 been studied following focal or partial brain radiotherapy, intelligence quotients (IQ) was less than 80 in about a quarter of 106 long term survivors, with younger children particularly at a higher risk of developing these sequelae (7,9). 107 3 dysfunction is cranial irradiation. PHA region unavoidably receives radiation with whole brain radiotherapy or if the tumour 111 itself is arising from this region. For the treatment of tumours adjacent to PHA but not involving it, it may be frequently a part 112 of radiotherapy planning target volume, which includes the gross tumour and a margin to account for any microscopic disease 113 and possible daily set up inaccuracies and thus receive significant doses. The region may also sometimes come in the entry / 114 exit path of radiation beams during treatment of tumours even away from this region. Radiation induced hormonal 115 abnormalities are generally dose dependent and may develop many years after irradiation. A significant radiation dose to the 116 PHA invariably results in some neuroendocrine dysfunction. The problem of endocrine dysfunction following cranial 117 irradiation may in fact have been underestimated as it is not always obvious on routine clinical examination and a detailed 118 clinical and biochemical evaluation is seldom done if the tumour is not involving the PHA. In the few studies evaluating this 119 issue in detail, the incidence of long-term neuroendocrine dysfunction following cranial irradiation have been found to be as 120 high as 50-91%, which increases with time (3, 8, 17, 18) . 121
Neuroendocrine dysfunction
Constine et al (17) evaluated endocrine status of 32 patients (mean age 19 years) who received radiotherapy for tumours not 122 directly involving PHA but this region received a dose ranging from 40-70Gy. After a median interval of seven years 123 following radiotherapy, 29 (91%) patients were found to have endocrine dysfunction. Abnormal results in one hormonal axis 124 (either thyroid, gonadal, prolactin, or adrenal function) was seen in 28%, in two hormonal axes in 25%, in three axes in 25% 125 and in all four axes in the remaining 12% patients. Growth hormone evaluation was not done in this study. 126
The incidence and severity of neuroendocrine dysfunction has been seen to be significantly higher in sellar and parasellar 127 tumours (8), use of radiotherapy (3), higher total radiation dose (17,19), higher dose per fraction (20) and younger age at 128 radiation (21). Schmieglow (19) in a prospective study of children with various intracranial tumours not involving PHA region 129 correlated the total radiation dose received by various pituitary hypothalamic volumes to predict growth hormone deficiency 130 (GHD). They found that the incidence of GHD could be reduced from 87% to 37% if radiation dose was limited to 37.5Gy to 131 90% of the PHA volume. 132
To reduce the impact of endocrine dysfunctions on physical, mental and sexual development, it is important to detect and treat 133 them timely. Early growth hormone replacement is the only way to minimise growth retardation caused by its deficiency 134 (Kanev 1991) but the treatment is expensive with significant financial implications, especially in our country. The annual cost 135 of GH replacement is approximately Rs 200,000.00, which is prohibitive for the vast majority of the Indian parents as is the 136 cost of LHRH analogues, which is useful to prevent early epiphyseal fusion and stunted growth in children with post radiation 137 or tumour related precocious puberty.
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4
Conventional radiotherapy techniques generally involve the use of 2-3 radiation beams covering the tumour and a margin of 1-140 3 cms for any subclinical disease and physical inaccuracies in the daily treatment delivery. The last decade has seen 141 tremendous technological advances in radiotherapy planning and accurate treatment delivery. Stereotactic radiosurgery (SRS) 142 and stereotactic radiotherapy (SRT) techniques involve firm and accurate immobilisation with fixed or relocatable frames, 143 high precision three-dimensional (3-D) target localisation with CT/CT-MRI fusion and focused radiation delivery. This is 144 achieved either with a multiheaded cobalt unit (gamma knife) or with multiple arcs using a modified conventional linear 145 accelerator. Such conventional stereotactic irradiation techniques typically produce spherical high dose volumes and are 146 therefore suitable only for small spherical lesions (23). A majority of the brain tumours considered for radiotherapy however 147
are not spherical and frequently extend to adjacent structures. To treat large non-spherical volumes with conventional SRS 148 requires the addition of multiple small spherical high dose volumes described as multiple isocentre treatment. The overlap of 149 high dose spheres results in dose inhomogeneity, which has been associated with a higher incidence of radiation induced 150 complications (24). It has been previously demonstrated that the optimum way of delivering high precision localised 151 irradiation to larger non-spherical targets is with the use of multiple conformal fixed fields with individualised shielding of 152 each radiation field conforming to the shape of the target (25). This principle of conformal therapy combined with the 153 precision of stereotactic localisation and focused radiation delivery is described as stereotactic conformal radiotherapy 154
(SCRT). 155
Traditionally, stereotactic irradiation has been delivered in a one session as single fraction radiosurgery. High doses of 156 radiation given in one fraction are known to be associated with a high risk of radiation induced damage to normal tissue and 157 this is particularly true for the central nervous system (26). Giving radiation in small individual doses allows the delivery of 158 higher radiation doses without serious injury to the normal tissues, which is especially important for normal CNS structures 159 (27). Single fraction SRS has been shown to be associated with considerable neurological toxicity to the optic apparatus 160 (28,29) the cranial nerves (29,30) and normal brain (31). With the application of high precision relocatable non-invasive 161 means of immobilisation, it has become possible to deliver stereotactic irradiation in a fractionated manner. The technique of 162 SCRT combines the precision of focused radiation delivery and the radiobiological advantages of fractionation. It also ensures 163 homogenous dose distribution within the irradiated volume further reducing the risk of damage. 164
The basic aim of high precision SCRT is to achieve a high dose differential between the tumour and the surrounding normal 165 tissues. This allows for either an increase in the tumour dose to improve local control or for a potential decrease in radiation 166 damage to the normal tissues. Further optimisation of the technique involving 3-4 conformal non-coplanar field arrangement 167 has shown a significant dose reduction to the normal brain (33). Preliminary experience, mainly in adults has shown this 168 technique to be feasible during the routine practice of a busy radiotherapy department. Early results in terms of local controlare same as that with conventional radiotherapy, with an increased sparing of the surrounding normal brain and adjacent 170 critical structures (32, 33, 34) . While the experience is limited in young children, a few reports have suggested it to be feasible 171 in this population also (35) . The technique has the potential to minimise the dose to any critical site close to the tumour like 172 pituitary-hypothalamic complex, cochlea, brain stem, optic apparatus and the mesial temporal lobes, which are believed to be 173 the common sites of radiation injury leading to late morbidity. 174 175
NEED FOR THE PRESENT STUDY 176
The finding of significant long-term effects in a large proportion of brain tumour survivors mandates the development of 177 treatment strategies designed to minimise their impact on the quality of life. Although the precise role of radiotherapy in the 178 causation of various post treatment sequelae is not established, it is generally believed to be at least partly responsible for these 179 effects. There have been attempts to modify the management in terms of avoiding, delaying radiotherapy or reducing the total 180 radiation dose to the tumour with a view to reduce its impact on the long-term toxicity. However, reduction of radiotherapy 181 doses to the tumour has been shown to result in poorer local control rates (36). Also, a majority of the patients in whom the 182 radiation is delayed eventually do require radiotherapy at later stages (37). There is also evidence that radiotherapy given 183 upfront yields superior disease control than radiotherapy given at the time of tumour progression (38,39). In light of this data, 184 there is therefore, an ever-increasing need to explore techniques of radiotherapy minimising the irradiation to the normal brain 185 and critical structures without compromising radiotherapy doses essential for tumour control. SCRT is a modern high-186 precision radiotherapy technique, which reduces the volume of normal brain irradiated and has the capability to minimise the 187 doses to critical structures. 188
The evidence of long term effects of focal irradiation so far is from retrospective studies and a few small prospective trials. 189
There is therefore, a great need to evaluate this issue in a prospective manner in a large number of patients. The present study 190 is designed to prospectively estimate the incidence and severity of neuropsychological, cognitive and neuroendocrine 191 dysfunction following radiotherapy delivered with conventional and stereotactic techniques and would be one of the most 192 comprehensive studies providing very important longitudinal and reliable data regarding these sequelae. The study involving 193 200 patients would be to the best of our knowledge not only the largest ever study conducted so far but also the only 194 randomised trial assessing these sequelae in patients receiving focal brain irradiation. 195
The study also examines whether the physical advantages of modern technological progress translate in clinical benefit. This If the present trial succeeds in reducing the incidence and severity of radiotherapy related sequelae by SCRT technique, it 200 would undoubtedly result in a tremendous benefit to these patients. A possible reduction in the neuroendocrine sequelae not 201 only will improve the quality of life of the patients but would also result in major financial saving. This is critical in patients 202 After 3 months of completing treatment, patients will undergo a post radiotherapy imaging scan (MRI/CT), which will act as a 289 baseline for future reference. Subsequent imaging studies will be carried out at anytime whenever clinically indicated. 290
Neuroendocrinological assessment (Appendix 2) 291
All patients before starting radiotherapy will be seen by an endocrinologist and a detailed clinical and biochemical 292 endocrinological assessment carried out. Subsequent assessments will be done at 6 months, 2, and 3 years and of follow up 293 annually thereafter. Assessments will be done as soon as the patient comes close to the appointed date of evaluation. If 294 feasible, assessments may also be carried out at an yearly basis after 3 and 5 years. Hormone replacement therapy will be 295 administered wherever appropriate. 296
Psychological and neurocognitive assessment (Appendix 3) 297
A team of clinical psychologist and occupational therapist will do psychological and neurocognitive assessment for each 298 patient before starting radiotherapy and at subsequent follow up at 6 months, 2 and 3 years of follow up [Appendix 4] and 299 annually thereafter. Weschler Intelligence Score Chart (WISC) for intelligence quotient (IQ), Rosenzweig Personality Factor 300 study (RPF) for behavioural assessment and Children's Depression inventory (CDI) will be used for paediatric patients. For 301 adults, assessment will be carried out by using a Weschler Memory Scale, WAIS and Bhatia Test of Intelligence for IQ, Sack's 302
Sentence Completion Test for adjustment and Hamilton Depression Rating Scale for behaviourial assessment. 303
Neurocognitive function will be assessed by a detailed examination with the help of LOTCA battery. A specially prepared 304 questionnaire (attached) will be also administered to each patient in order to evaluate any physical or psychosocial factors 305 creating a disharmony in the school or home life. Activities of daily living will be recorded at each follow up using modified 306
Barthel's Index. 307
ANALYSIS 308
The study will accrue 200 patients over a four-year period and the evaluation after treatment will be extended for a further 309 period of minimum 3 years. All surviving patients will have a minimum follow up of at least 3 years. The expected median 310 follow up at the time of final analysis will be four and a half years. 311
The probability of hormonal, intellectual, cognitive and neurological impairment will be collected prospectively and difference 312 in the estimated incidence of these dysfunctions between the two arms will be assessed for statistical significance. The mean 313 change over a period of time in the neuropsychological and cognitive assessment scores obtained by WAIS, LOTCA battery, 314
Weschler memory scale etc of the patient populations in the two arms will be compared using linear mixed model. Similarly, 315 the mean change in the hormonal levels between the two treatment arms will also be compared using the mean comparison t 316 test. A Cox proportional hazard model will be applied to evaluate the independent impact of the randomisation arm and 317 various stratification parameters on the neuropsychological and neuroendocrine dysfunction. , 1950 -1981 . Int J Radiat Oncol Biol Phys 18, 599-603, 1990 43-50,1998. 376 Patient Initial SCRT NO. 30. Engenhart, R, Kimmig, BN, Hover, KH, Wowra, B, Romahn, J, Lorenz, WJ, Van-Kaick, G, Wannenmacher, M. Long-377 term follow-up for brain metastases treated by percutaneous stereotactic single high-dose irradiation. 604   605  606  607  608  609  610  611  612  613  614  615  616  617  618  619  620  621  622  623  624  625  626  627  628  629  630  631  632  633  634  635  636  637  638  639  640  641 The SCRT Trial Definition of endocrine dysfunction was defined as dysfunction in atleast one axis compared to baseline evaluation or previous evaluation. The neuroendocrine evaluation tools consisted of both clinical & biochemical tests as assessed for all the endocrine axes in the present randomized study. Away from HPA (>2cm) P =0
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